Relationship Between Cardiopulmonary Exercise Testing and Ca-P in Chronic Kidney Disease (CKD)

Ckd-Mbd Clinical Trial

Official title:

Evaluation of the Relationship Between Cardiopulmonary Exercise Testing (CPET ) Abnormalities and Ca-P Status in CKD Stage3-5

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04013139
• Other study ID #: SBMU2314
• Status: Completed
• Start date: January 1, 2020
• Est. completion date: October 1, 2021

Study information

• Verified date: January 2022
• Source: Shahid Beheshti University of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Reductions in exercise capacity associated with exercise intolerance augment cardiovascular disease risk and predict mortality in chronic kidney disease. This study utilized cardiopulmonary exercise testing to (a) investigate mechanisms of exercise intolerance; (b) unmask subclinical ca and p and vitamin D abnormalities that may precede cardiovascular disease in chronic kidney disease.

Description:

Cardiopulmonary exercise testing will carry out in Stage 3-5 chronic kidney disease patients ; estimated glomerular filtration rate <60 ml/min/1.73 m2) and biochemistry will be added (Ca P Via D PTH FGF23).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: October 1, 2021
• Est. primary completion date: August 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• CKD Patients with GFR <60 non-dialysis

• age<18

Exclusion Criteria:

• HTN

• not signing consent

• active coronary disease

Related Conditions & MeSH terms

• Chronic Kidney Disease-Mineral and Bone Disorder
• Ckd-Mbd

Intervention

Diagnostic Test:
• CPET
CPET

Locations

Country	Name	City	State
Iran, Islamic Republic of	Nooshin Dalili	Tehran

Sponsors (1)

Lead Sponsor	Collaborator
Shahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Calcium x phosphorus change in stage 3-5	CaxP change	12 MONTHS
Primary	CPET score change	Evaluation of CPET score change	12 MONTHS
Secondary	Renal Function change	GFR change	12 MONTHS